Phase 4Completed

CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events

A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS)

Sponsor
Pfizer (Industry)
Enrollment
2,800 planned
Conditions
Major Coronary Event; Cerebrovascular Accident; Coronary Artery Bypass Graft; Angina, Unstable; Revascularization
Interventions
Atorvastatin
Ages
adults, older adults
Registry
NCT00327418

Full record on ClinicalTrials.gov

From the registry

A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy, microalbuminuria, macroalbuminuria, or who currently smoke, but who do not have established corornary heart disease or other macrovascular disease.

Primary outcomes

  • Time from randomization to the occurrence of a primary clinical endpoint
  • i.e. major coronary event or CABG or other coronary revascularization procedure
  • or unstable angina or resuscitated cardiac arrest or stroke.

History

  1. Last registry update

  2. Registered

  3. Study completion

  4. Started